Hemostemix Inc. (CVE:HEM – Get Free Report) was up 30% on Wednesday . The stock traded as high as C$0.15 and last traded at C$0.13. Approximately 430,289 shares changed hands during trading, a decline of 10% from the average daily volume of 480,285 shares. The stock had previously closed at C$0.10.
Hemostemix Trading Up 30.0%
The company has a fifty day simple moving average of C$0.10 and a two-hundred day simple moving average of C$0.14. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company has a market capitalization of C$18.94 million, a P/E ratio of -3.79 and a beta of 0.20.
Insider Buying and Selling at Hemostemix
In related news, Director Peter Alan Lacey bought 200,000 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were bought at an average cost of C$0.15 per share, for a total transaction of C$30,000.00. Corporate insiders own 10.43% of the company’s stock.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- What is a Bond Market Holiday? How to Invest and Trade
- Top 5 Stocks Hedge Funds Are Buying Right Now
- Canada Bond Market Holiday: How to Invest and Trade
- Viking Holdings Posts Strong Q1, Eyes Growth Ahead
- The Most Important Warren Buffett Stock for Investors: His Own
- 2 Reasons Netflix’s 40% Rally Is Far From Over
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
